{"id":65306,"date":"2026-05-14T14:36:04","date_gmt":"2026-05-14T06:36:04","guid":{"rendered":"https:\/\/flcube.com\/?p=65306"},"modified":"2026-05-14T14:36:05","modified_gmt":"2026-05-14T06:36:05","slug":"abb-bio-tech-launches-phase-i-ii-trial-of-recombinant-rsv-vaccine-cho-cell-derived-adjuvanted-candidate-shows-enhanced-pre-f-protein-expression-and-stability","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=65306","title":{"rendered":"Ab&amp;b Bio-Tech Launches Phase I\/II Trial of Recombinant RSV Vaccine \u2013 CHO Cell-Derived Adjuvanted Candidate Shows Enhanced Pre-F Protein Expression and Stability"},"content":{"rendered":"\n<p><strong>Ab&amp;b Bio-Tech Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2627:HKG\">HKG: 2627<\/a>) announced the initiation of a <strong>Phase I\/II clinical study<\/strong> for its <strong>self-developed recombinant respiratory syncytial virus (RSV) vaccine (CHO cell-derived) (adjuvanted)<\/strong>, designed for the <strong>prevention of RSV infection<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-development-milestone\">Clinical Development Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Ab&amp;b Bio-Tech Co., Ltd. (HKG: 2627)<\/td><\/tr><tr><td><strong>Trial Phase<\/strong><\/td><td>Phase I\/II<\/td><\/tr><tr><td><strong>Status<\/strong><\/td><td>Study initiated<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Prevention of RSV infection<\/td><\/tr><tr><td><strong>Vaccine Platform<\/strong><\/td><td>Recombinant CHO cell-derived with adjuvant<\/td><\/tr><tr><td><strong>Target Antigen<\/strong><\/td><td>Modified pre-F protein<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-vaccine-technology-amp-preclinical-advantages\">Vaccine Technology &amp; Preclinical Advantages<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Expression System:<\/strong> <strong>CHO (Chinese Hamster Ovary) cells<\/strong> \u2013 established mammalian expression platform<\/li>\n\n\n\n<li><strong>Key Antigen:<\/strong> <strong>Modified pre-F protein<\/strong> \u2013 stabilized conformation that elicits potent neutralizing antibodies<\/li>\n\n\n\n<li><strong>Adjuvant Formulation:<\/strong> Enhanced immunogenicity through proprietary adjuvant system<\/li>\n\n\n\n<li><strong>Preclinical Differentiation vs. Marketed Vaccines:<\/strong><\/li>\n\n\n\n<li><strong>Higher pre-F expression levels<\/strong> \u2013 increased antigen yield and consistency<\/li>\n\n\n\n<li><strong>Better thermal stability<\/strong> \u2013 improved storage and distribution logistics<\/li>\n\n\n\n<li><strong>Superior immunogenicity<\/strong> \u2013 stronger immune response in preclinical models<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-competitive-landscape\">Market Context &amp; Competitive Landscape<\/h2>\n\n\n\n<p><strong>RSV Vaccine Market Dynamics:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>High Unmet Need:<\/strong> RSV causes ~33 million lower respiratory tract infections annually in children under 5 globally<\/li>\n\n\n\n<li><strong>Elderly Population:<\/strong> Significant disease burden in adults \u226560 years with comorbidities<\/li>\n\n\n\n<li><strong>Recent Approvals:<\/strong> GSK&#8217;s Arexvy and Pfizer&#8217;s Abrysvo established proof-of-concept for pre-F based vaccines<\/li>\n\n\n\n<li><strong>Market Opportunity:<\/strong> Estimated $10+ billion global RSV vaccine market by 2030<\/li>\n<\/ul>\n\n\n\n<p><strong>Competitive Differentiation:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>CHO Cell Platform:<\/strong> Offers manufacturing scalability advantages over other expression systems<\/li>\n\n\n\n<li><strong>Enhanced Stability:<\/strong> Better thermal stability could reduce cold chain requirements and expand access<\/li>\n\n\n\n<li><strong>Higher Immunogenicity:<\/strong> Potential for improved efficacy or reduced dosing requirements<\/li>\n\n\n\n<li><strong>Domestic Innovation:<\/strong> First Chinese-developed RSV vaccine candidate to reach clinical trials<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-significance-for-ab-amp-b-bio-tech\">Strategic Significance for Ab&amp;b Bio-Tech<\/h2>\n\n\n\n<p>This RSV vaccine represents a strategic expansion beyond the company&#8217;s traditional biosimilars portfolio into <strong>novel vaccine development<\/strong>. Success in clinical development could position Ab&amp;b as a leader in China&#8217;s emerging innovative vaccine market while providing opportunities for global partnerships.<\/p>\n\n\n\n<p>The <strong>adjuvanted formulation<\/strong> addresses the critical need for enhanced immune responses in elderly populations, who represent a primary target demographic for RSV vaccination alongside pediatric populations.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-timeline-amp-commercial-outlook\">Development Timeline &amp; Commercial Outlook<\/h2>\n\n\n\n<p>The Phase I\/II trial will assess safety, tolerability, and immunogenicity across multiple age groups. Given the established regulatory pathways for RSV vaccines following recent approvals, Ab&amp;b could potentially pursue accelerated development timelines if preclinical advantages translate to clinical benefit.<\/p>\n\n\n\n<p>Success would provide Ab&amp;b with a high-value proprietary asset in the rapidly growing infectious disease prevention market, complementing the company&#8217;s existing commercial infrastructure.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development timelines, regulatory approvals, and therapeutic potential of the RSV vaccine candidate. Actual results may differ due to risks including clinical trial outcomes, regulatory requirements, competitive dynamics, and market adoption patterns.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2026051301230_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026051301230_c.\"><\/object><a id=\"wp-block-file--media-dd8b2501-8a11-4f01-85ed-85f822931400\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2026051301230_c.pdf\">2026051301230_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2026051301230_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-dd8b2501-8a11-4f01-85ed-85f822931400\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Ab&amp;b Bio-Tech Co., Ltd. (HKG: 2627) announced the initiation of a Phase I\/II clinical study&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[4291,62,4334,12],"class_list":["post-65306","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-abb-bio-tech","tag-clinical-trial-approval-initiation","tag-hkg-2627","tag-vaccine"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Ab&amp;b Bio-Tech Launches Phase I\/II Trial of Recombinant RSV Vaccine \u2013 CHO Cell-Derived Adjuvanted Candidate Shows Enhanced Pre-F Protein Expression and Stability - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Ab&amp;b Bio-Tech Co., Ltd. (HKG: 2627) announced the initiation of a Phase I\/II clinical study for its self-developed recombinant respiratory syncytial virus (RSV) vaccine (CHO cell-derived) (adjuvanted), designed for the prevention of RSV infection.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=65306\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ab&amp;b Bio-Tech Launches Phase I\/II Trial of Recombinant RSV Vaccine \u2013 CHO Cell-Derived Adjuvanted Candidate Shows Enhanced Pre-F Protein Expression and Stability\" \/>\n<meta property=\"og:description\" content=\"Ab&amp;b Bio-Tech Co., Ltd. (HKG: 2627) announced the initiation of a Phase I\/II clinical study for its self-developed recombinant respiratory syncytial virus (RSV) vaccine (CHO cell-derived) (adjuvanted), designed for the prevention of RSV infection.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=65306\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-14T06:36:04+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-14T06:36:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65306#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65306\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Ab&amp;b Bio-Tech Launches Phase I\\\/II Trial of Recombinant RSV Vaccine \u2013 CHO Cell-Derived Adjuvanted Candidate Shows Enhanced Pre-F Protein Expression and Stability\",\"datePublished\":\"2026-05-14T06:36:04+00:00\",\"dateModified\":\"2026-05-14T06:36:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65306\"},\"wordCount\":465,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Ab&amp;B Bio-Tech\",\"Clinical trial approval \\\/ initiation\",\"HKG: 2627\",\"Vaccine\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65306#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65306\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=65306\",\"name\":\"Ab&amp;b Bio-Tech Launches Phase I\\\/II Trial of Recombinant RSV Vaccine \u2013 CHO Cell-Derived Adjuvanted Candidate Shows Enhanced Pre-F Protein Expression and Stability - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-14T06:36:04+00:00\",\"dateModified\":\"2026-05-14T06:36:05+00:00\",\"description\":\"Ab&b Bio-Tech Co., Ltd. (HKG: 2627) announced the initiation of a Phase I\\\/II clinical study for its self-developed recombinant respiratory syncytial virus (RSV) vaccine (CHO cell-derived) (adjuvanted), designed for the prevention of RSV infection.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65306#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65306\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65306#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ab&amp;b Bio-Tech Launches Phase I\\\/II Trial of Recombinant RSV Vaccine \u2013 CHO Cell-Derived Adjuvanted Candidate Shows Enhanced Pre-F Protein Expression and Stability\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Ab&amp;b Bio-Tech Launches Phase I\/II Trial of Recombinant RSV Vaccine \u2013 CHO Cell-Derived Adjuvanted Candidate Shows Enhanced Pre-F Protein Expression and Stability - Insight, China&#039;s Pharmaceutical Industry","description":"Ab&b Bio-Tech Co., Ltd. (HKG: 2627) announced the initiation of a Phase I\/II clinical study for its self-developed recombinant respiratory syncytial virus (RSV) vaccine (CHO cell-derived) (adjuvanted), designed for the prevention of RSV infection.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=65306","og_locale":"en_US","og_type":"article","og_title":"Ab&amp;b Bio-Tech Launches Phase I\/II Trial of Recombinant RSV Vaccine \u2013 CHO Cell-Derived Adjuvanted Candidate Shows Enhanced Pre-F Protein Expression and Stability","og_description":"Ab&b Bio-Tech Co., Ltd. (HKG: 2627) announced the initiation of a Phase I\/II clinical study for its self-developed recombinant respiratory syncytial virus (RSV) vaccine (CHO cell-derived) (adjuvanted), designed for the prevention of RSV infection.","og_url":"https:\/\/flcube.com\/?p=65306","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-14T06:36:04+00:00","article_modified_time":"2026-05-14T06:36:05+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=65306#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=65306"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Ab&amp;b Bio-Tech Launches Phase I\/II Trial of Recombinant RSV Vaccine \u2013 CHO Cell-Derived Adjuvanted Candidate Shows Enhanced Pre-F Protein Expression and Stability","datePublished":"2026-05-14T06:36:04+00:00","dateModified":"2026-05-14T06:36:05+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=65306"},"wordCount":465,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Ab&amp;B Bio-Tech","Clinical trial approval \/ initiation","HKG: 2627","Vaccine"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=65306#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=65306","url":"https:\/\/flcube.com\/?p=65306","name":"Ab&amp;b Bio-Tech Launches Phase I\/II Trial of Recombinant RSV Vaccine \u2013 CHO Cell-Derived Adjuvanted Candidate Shows Enhanced Pre-F Protein Expression and Stability - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-14T06:36:04+00:00","dateModified":"2026-05-14T06:36:05+00:00","description":"Ab&b Bio-Tech Co., Ltd. (HKG: 2627) announced the initiation of a Phase I\/II clinical study for its self-developed recombinant respiratory syncytial virus (RSV) vaccine (CHO cell-derived) (adjuvanted), designed for the prevention of RSV infection.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=65306#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=65306"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=65306#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Ab&amp;b Bio-Tech Launches Phase I\/II Trial of Recombinant RSV Vaccine \u2013 CHO Cell-Derived Adjuvanted Candidate Shows Enhanced Pre-F Protein Expression and Stability"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65306","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=65306"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65306\/revisions"}],"predecessor-version":[{"id":65308,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65306\/revisions\/65308"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=65306"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=65306"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=65306"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}